Brief: Deciphera Pharmaceuticals Plans To Initiate Insight Pivotal Phase 3 Clinical Study In Second Half Of 2023

Deciphera Pharmaceuticals

24/01/2023 23:16

Jan 24 (Reuters) - Deciphera Pharmaceuticals Inc
 DCPH.O :
    * DECIPHERA PHARMACEUTICALS PRESENTS RESULTS FROM CTDNA
ANALYSIS
OF INTRIGUE PHASE 3 CLINICAL STUDY AT THE AMERICAN SOCIETY OF
CLINICAL ONCOLOGY PLENARY SERIES SESSION
    * DECIPHERA PHARMACEUTICALS INC - COMPANY PLANS TO INITIATE
INSIGHT PIVOTAL PHASE 3 CLINICAL STUDY IN SECOND HALF OF 2023
    * DECIPHERA PHARMACEUTICALS INC - QINLOCK WAS GENERALLY
WELL-TOLERATED AND SAFETY PROFILES WERE CONSISTENT WITH PRIMARY
ANALYSIS OF INTRIGUE STUDY
    * DECIPHERA- SECOND-LINE GIST PATIENTS WITH MUTATIONS IN KIT
EXON
11 + 17/18 DEMONSTRATED SUBSTANTIAL CLINICAL BENEFIT FROM
QINLOCK BUT NOT SUNITINIB

Source text for Eikon:  ID:nBwbNRg0Ga 
Further company coverage:  DCPH.O 
 ((Reuters.Briefs@thomsonreuters.com;))